FDA clinical holds

An FDA hold reaches opacalim before SK Biopharmaceuticals pays the $350 million at closing

Kiwoom Securities says the FDA has suspended new enrollment in one of two registrational trials of the epilepsy drug SK Biopharmaceuticals agreed to license from Biohaven last month, and the closing payment is still outstanding.